Data from a hospital based case-control study of lung cancer in Western Europe were used to examine changes in the risk of developing lung cancer after changes in habits of cigarette smoking. Only data for subjects who had smoked regularly at some time in their lives were included. The large size of the study population (7181 patients and 11 006 controls) permitted precise estimates of the effect of giving up smoking.
Introduction
In most populations the prevalence of lung cancer among people who smoke cigarettes is lower in those with a low cigarette consumption and in ex-smokers. '-5 Using data from a large international case-control study, we considered two issues related to prevention of lung cancer-namely, how the reduction in risk of developing lung cancer after giving up smoking is influenced by previous patterns of cigarette smoking and how the change in risk of developing lung cancer after a reduction in the number of cigarettes smoked a day or a switch from non-filter to filter brands compares with the change after giving up.
Subjects and methods
A description of the methods of collecting data has been given previously.6 In brief, a case-control interview study of lung cancer was carried out in seven study areas in five Western European countries. Patients admitted to hospital in 1976-80 for suspected lung cancer were interviewed while in hospital. Only patients with histologically confirmed lung cancer were entered into the study population. Interviews were carried out soon after admission; patients discharged before being interviewed were excluded. Nearly all patients contacted agreed to participate. For each patient two controls, matched for age at diagnosis (within five years), sex, centre, and, if possible, category of hospital accommodation, were selected from other hospital patients in whom diseases not related to tobacco had been 1953 BRITISH MEDICAL JOURNAL VOLUME 288 30 JUNE 1984 filter to filter brands. Profiles could be computed only for those with a complete smoking history; others were coded as missing. Summary relative risks of developing lung cancer associated with several smoking variables were computed over strata defined by centre and, when appropriate, other factors, using the method of Gart.' The Mantel extension procedure8 was used to test for linear trend across multiple exposure categories, with weights defined by consecutive integers. In addition, a multivariate regression analysis for matched case-control data was carried out,9 10 the results of which closely paralleled those from analysis of unmatched, stratified data. Because duration of smoking habit was an important risk and confounding factor in analyses of patterns of giving up smoking all relative risks were adjusted by categories of duration-namely, one to 19, 20-39, 40-49, and 50 or more years of use.
Results Table I shows that most of the subjects included in the present study were smoking at the time of interview and that a higher proportion of women than men were still smoking. The risk of developing lung cancer dropped sharply after giving up smoking with the gradient of decrease similar in both men and women. The patterns of decrease were similar after further adjustment for number of cigarettes smoked a day.
In each category of duration of smoking habit the risk of developing lung cancer decreased as the number of years since stopping smoking increased (table II); in men, however, the rate of decline was greater in those who had smoked for a shorter time (p < 0 001). For men who had smoked for one to 19 years the risk of developing lung cancer after 10 years of not smoking dropped to less than one third of that for current smokers, but even for men who had smoked for 50 years or more the risk was still 900o of that for men who continued to smoke. We noted the duration of smoking habit, the number of cigarettes smoked each day, and the names of four brands previously smoked. Mostsubjects(15 834(87 1 %))hadsmokedthreeorfewerbrands. When more than four brands were reported during the interview coding procedures varied slightly among study centres. At most centres consecutive brands were combined, filter or non-filter type being coded as missing if the consecutive brands differed in this respect. Less often the four brands used for the longest duration were coded. Using information about brands we created a smoking profile for each subject, detailing changes in the number of cigarettes smoked each day and from non-(The risks for lifelong non-smokers relative to current smokers who had been smoking for one to 19 years were 0 25 for men and 0 59 for women. Thus, after 10 years of not smoking, the risk of developing lung cancer for men who had smoked for one to 19 years approached that for lifelong non-smokers; but risks remained substantially raised for subjects who had smoked for more than 19 years, even after 10 years of not smoking. For women the level of risk found in nonsmokers was attained after five years of not smoking in those who had smoked for one to 19 years, but in longer term smokers risks remained raised even after 10 years of not smoking.) Table III shows relative risks for years since stopping smoking according to various other variables. In men the rate of decline in relative risks with stopping smoking varied significantly (p<0.05) between categories of number smoked each day, with an increasingly greater proportional reduction in risk in those who had not smoked for 10 years or more and had previously smoked a greater number each day. In women no such significant differences were seen. No significant differences in trend were seen according to type of cigarette smoked (only filter, only non-filter, or both), but there was some indica-tion of a greater reduction in risk for those who inhaled less often or deeply.
We also expressed relative risks, adjusted for duration of cigarette use in years, by changes in habit during the course of smoking life. Small numbers prevented us giving the results for women. The analyses in tables IV and VI were repeated, adjusting for number of cigarettes smoked each day and age at diagnosis; the results were not materially affected. We also found that the patterns of risk were similar when subjects who had changed brands only once in their smoking experience were studied.
Discussion
Smokers who smoke filter or lower tar brands, who smoke fewer cigarettes a day, or who give up smoking are known to be at lower risk of developing lung cancer.'-6 Our analyses help to measure the effect of such modifications in smoking habits. The results show that changes in patterns of cigarette smoking that lower exposure were associated with lower risks of developing lung cancer but, when compared with completely stopping smoking, the reductions in risk were small. This study also shows that the decline in relative risk after stopping smoking was greater in those who had smoked for shorter periods. The subjects who had smoked for one to 19 years returned to the risk level of lifetime non-smokers within five to 10 years after stopping smoking. This finding suggests that the carcinogenic effects of smoking can be minimised by stopping smoking if the habit is not continued for too long. This should induce people starting to smoke regularly and short term smokers to stop before changes become irreversible. Those subjects who gave up smoking after 40 years of cigarette use were still at a substantially increased relative risk 10 years after stopping compared with those who had never smoked and, indeed, were unlikely ever to approach the level of risk found in those who had never smoked. The finding of a smaller relative decline in long term smokers who give up is consistent with that reported for British doctors," among whom the arithmetic excess in death due to lung cancer in smokers who give up compared with lifetime non-smokers was almost constant.
Several potential biases in this hospital based study (resulting from the method of case acquisition, choice of control diseases, and differences in the referral patterns of the patients and controls) have been discussed previously6 and were thought to be minimal. Recall bias was also thought to be small as general knowledge of the association between smoking and lung cancer was high in all groups, respondents were told only that the survey was to gather health information, and many patients were unaware of their specific diagnosis at the time of interview. Furthermore, all the subjects in this analysis acknowledged themselves to be smokers. There may have been some gaps in the smoking histories as we do not know how often patients stopped smoking between changes in brand or while smoking a single brand. By comparing age at interview with age at start of smoking habit plus time since giving up plus years of use we estimated that 17 690 (97%) of the subjects who had smoked had done so continuosuly or with a total smoking free interval of two years or less. Another limitation was that the questionnaire recorded no more that four different brands of cigarettes. The procedures that were used for those smoking five or more brands would have tended to underestimate exposure, particularly the duration of use. The rarity of this occurrence, however, argued against any appreciable impact on patterns of risk.
In summary, our results suggest that reducing the risk of developing lung cancer induced by cigarette smoking in middle aged and older smokers requires primary emphasis on stopping the smoking habit or lowering the amount smoked each day. Smoking only filter brands was also associated with a lowered risk (although changing from a non-filter to a filter cigarette had only a relatively small impact on risk of developing lung cancer) but was not as effective a preventive measure as giving up completely.
The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? I PEACOCK, R B TATTERSALL Abstract Patients with maturity onset diabetes that is poorly controlled on maximal doses of oral hypoglycaemic agents are difficult to treat. A prospective randomised crossover study was performed in 58 predominantly non-obese patients on maximal doses of glibenclamide or metformin, or both, to find out if insulin would improve control or well being. The patients were given daily injections of up to 48 units of highly purified porcine lente insulin. Glycaemic control was improved by 15% or more in only 18 patients; 14 others felt better but their diabetes was no better controlled. Those whose control was improved by insulin could not be distinguished by age, duration of diabetes, body mass index, or their own treatment preference. C peptide concentrations, however, did help predict the response to insulin, the fasting C peptide to glucose ratio being considerably lower in those patients whose control was better on insulin.
These findings suggest that a simple insulin regimen does not necessarily lead to better glycaemic control in maturity onset diabetes. Nevertheless, a trial of insulin is often justified since it poses few practical difficulties and makes some patients feel better even if their control is not improved. A more complex regimen might improve control in more cases, but it might also be less acceptable to older patients.
Introduction
At first sight treatment of maturity onset diabetes seems simple. The basis is diet, especially for overweight patients. When this fails a sulphonylurea or a biguanide is added, or a combination of the two if either alone does not achieve good control. Finally, "when oral agents are used and found to be ineffective, either initially or secondarily, insulin should be substituted"'-the implication being that all will then be well. In practice treatment of maturity onset diabetes is less straightforward. It is hard to change eating habits, and dietary advice is often ignored. Many patients progress to oral hypoglycaemic agents (subsequently referred to as "tablets") but still remain poorly controlled. Both doctor and patient may be reluctant to accept that tablet treatment has failed and move on to insulin. This reluctance may be justified since there is no evidence that insulin treatment necessarily produces better control of maturity onset diabetes. Indeed, there are many patients whose control appears to be worse on insulin, perhaps not surprisingly because maturity onset diabetes is a complex and heterogenous disorder resulting from insulin resistance as well as insulin deficiency.2-4
